A Study to Evaluate the Incidence and Clinical Characteristics of Interstitial Lung Disease (ILD) Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKIs) Gefitinib or Erlotinib in Taiwanese Patients with Adavanced Non Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update:
19 Dec 2015
Note:
-
Adis is an information provider.
-
Final gross price and currency may vary according to local VAT and billing address.
-
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
-
A link to download a PDF version of the trial profile will be included in your email receipt.